Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The tumor suppressor TP53 is the most frequently mutated gene product in human cancer. Close to half of all solid tumors carry inactivating mutations in the TP53 gene, while in the remaining cases, TP53 activity is abrogated by other oncogenic events, such as hyperactivation of its endogenous repressors MDM2 or MDM4. Despite identification of hundreds of genes regulated by this transcription factor, it remains unclear which direct target genes and downstream pathways are essential for the tumor suppressive function of TP53. We set out to address this problem by generating multiple genomic data sets for three different cancer cell lines, allowing the identification of distinct sets of TP53-regulated genes, from early transcriptional targets through to late targets controlled at the translational level. We found that although TP53 elicits vastly divergent signaling cascades across cell lines, it directly activates a core transcriptional program of ∼100 genes with diverse biological functions, regardless of cell type or cellular response to TP53 activation. This core program is associated with high-occupancy TP53 enhancers, high levels of paused RNA polymerases, and accessible chromatin. Interestingly, two different shRNA screens failed to identify a single TP53 target gene required for the anti-proliferative effects of TP53 during pharmacological activation in vitro. Furthermore, bioinformatics analysis of thousands of cancer genomes revealed that none of these core target genes are frequently inactivated in tumors expressing wild-type TP53. These results support the hypothesis that TP53 activates a genetically robust transcriptional program with highly distributed tumor suppressive functions acting in diverse cellular contexts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 2×
“We activated TP53 specifically with Nutlin-3, a small molecule inhibitor of the TP53-MDM2 interaction (Vassilev et al. 2004), which induces a global pattern of TP53 binding to chromatin similar to that induced by DNA damage (Verfaillie et al. 2016).”
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398 · cited 1×
“…potential gap in our knowledge has triggered many efforts to identify novel TP53-regulated genes and pathways, with various teamspointingtoautophagy, ferroptosis,ormetabolismasthekey to understanding tumor suppression by TP53 (Vousden and Ryan 2009; Kenzelmann Broz et al. 2013; Jiang et al. 2015).”
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“In the absence of cellular stress, basal TP53 activity is repressed by several mechanisms, including masking of its trans-activation domains, proteasomal degradation, and reduced mRNA translation (Leach et al. 1993; Kubbutat et al. 1997; Takagi et al. 2005).”
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 2×
“In response to myriad stress stimuli, these repressive mechanisms are relieved, leading to unmasking of the TP53 transactivation domains, increased TP53 protein levels, and subsequent transactivation of TP53 target genes (Vousden and Prives 2009).”
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · cited 2×
“To test these ideas, we analyzed genomic data for 4429 samples from 19 different cancer types available through The Cancer Genome Atlas (TCGA, http:// cancergenome.nih.gov/) (Lawrence et al. 2014).”
A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2005.10.043 · Cited by 1,141 · cited 1×
“…are bound by TP53 within arbitrary distances from their promoters and that show changes in mRNA expression at various times after TP53 activation (Wei et al. 2006; Li et al. 2012a; Nikulenkov et al. 2012; Kenzelmann Broz et al. 2013; Menendez et al. 2013; Schlereth et al. 2013; Wang etal.2014).”
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
Vousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959 · cited 1×
“…potential gap in our knowledge has triggered many efforts to identify novel TP53-regulated genes and pathways, with various teamspointingtoautophagy, ferroptosis,ormetabolismasthekey to understanding tumor suppression by TP53 (Vousden and Ryan 2009; Kenzelmann Broz et al. 2013; Jiang et al. 2015).”
Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533
Kenzelmann Broz, D., Spano Mello, S., Bieging, K. T., Jiang, D., Dusek, R. L., Brady, C. A., Sidow, A., & Attardi, L. D. (2013) · Genes & Development · doi:10.1101/gad.212282.112 · Cited by 443 · cited 4×
“…potential gap in our knowledge has triggered many efforts to identify novel TP53-regulated genes and pathways, with various teamspointingtoautophagy, ferroptosis,ormetabolismasthekey to understanding tumor suppression by TP53 (Vousden and Ryan 2009; Kenzelmann Broz et al. 2013; Jiang et al. 2015).”
InfluentialLi, M., He, Y., Dubois, W., Wu, X., Shi, J., & Huang, J. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.01.020 · Cited by 264 · cited 3×
“Similarly, two different reports employing TP53 alleles defective for transactivation of pro-apoptotic genes concluded that TP53-dependent apoptosis is either required (Timofeev et al. 2013), or dispensable (Li et al. 2012b) for tumor suppression.”
Menendez, D., Nguyen, T.-A., Freudenberg, J. M., Mathew, V. J., Anderson, C. W., Jothi, R., & Resnick, M. A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt504 · Cited by 154 · cited 1×
“…are bound by TP53 within arbitrary distances from their promoters and that show changes in mRNA expression at various times after TP53 activation (Wei et al. 2006; Li et al. 2012a; Nikulenkov et al. 2012; Kenzelmann Broz et al. 2013; Menendez et al. 2013; Schlereth et al. 2013; Wang etal.2014).”
The transcription factor p53: Not a repressor, solely an activator.
Fischer, M., Steiner, L., & Engeland, K. (2014) · Cell Cycle · doi:10.4161/15384101.2014.949083 · Cited by 153
Schlereth, K., Heyl, C., Krampitz, A.-M., Mernberger, M., Finkernagel, F., Scharfe, M., Jarek, M., Leich, E., Rosenwald, A., & Stiewe, T. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003726 · Cited by 87
Multiplex enhancer-reporter assays uncover unsophisticated TP53 enhancer logic
Verfaillie, A., Svetlichnyy, D., Imrichova, H., Davie, K., Fiers, M., Kalender Atak, Z., Hulselmans, G., Christiaens, V., & Aerts, S. (2016) · Genome Research · doi:10.1101/gr.204149.116 · Cited by 82
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53
Sullivan, K. D., Padilla-Just, N., Henry, R. E., Porter, C. C., Kim, J., Tentler, J. J., Eckhardt, S. G., Tan, A. C., DeGregori, J., & Espinosa, J. M. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.965 · Cited by 67
Self-citation
Cited by
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Lacroix, M., Riscal, R., Arena, G., Linares, L. K., & Le Cam, L. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.002 · Cited by 373
p53 and Tumor Suppression: It Takes a Network
Boutelle, A. M., & Attardi, L. D. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.12.011 · Cited by 317
Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements
Shah, N. M., Jang, H. J., Liang, Y., Maeng, J. H., Tzeng, S.-C., Wu, A., Basri, N. L., Qu, X., Fan, C., Li, A., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01349-3 · Cited by 175
Zhou, X., Singh, M., Sanz Santos, G., Guerlavais, V., Carvajal, L. A., Aivado, M., Zhan, Y., Oliveira, M. M. S., Westerberg, L. S., Annis, D. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1741 · Cited by 169
Metadata
- Authors
- Andrysik, Z., Galbraith, M. D., Guarnieri, A. L., Zaccara, S., Sullivan, K. D., Pandey, A., MacBeth, M., Inga, A., & Espinosa, J. M.
- Venue
- Genome Research
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-09-13
- Volume
- 27
- Issue
- 10
- Pages
- 1645-1657
- ISSN
- 1088-9051 (ISSN-L)
- 1549-5469
- OpenAlex
- W2755290882
- Cited by
- 154
- References
- 19
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.